Why insulin is needed in type 2 diabetes
Over time, insulin resistance and progressive beta-cell decline can make oral agents and GLP-1 medications insufficient. Insulin is added to close the gap. Insulin use in type 2 diabetes is common and does not by itself mean the disease has "converted" to type 1.
Why C-peptide matters
C-peptide is a marker of remaining insulin production. Patients with preserved C-peptide generally have more residual beta-cell function and, on average, better metabolic responses to surgery. Very low C-peptide suggests limited beta-cell reserve and less likelihood of coming off insulin.
What metabolic surgery may and may not do
- Many insulin-using patients reduce their insulin dose after surgery.
- Some come off insulin entirely; this is more likely with shorter disease duration and higher C-peptide.
- Others remain on insulin at a lower dose with better control.
- No responsible program guarantees discontinuation of insulin.
Evaluation specifics
Evaluation for an insulin-using patient typically adds C-peptide, anti-GAD antibodies (to rule out LADA), and a careful review of insulin regimen and hypoglycemia history. Perioperative insulin management is planned in advance.
Ready for an individualized evaluation?
A physician evaluation is the only way to determine candidacy. Outcomes vary; no result is guaranteed.